Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Karyopharm Therapeutics ( (KPTI) ) just unveiled an update.
On March 24, 2026, Karyopharm Therapeutics Inc. entered into a securities purchase agreement with RA Capital Management for a private placement of common stock, pre-funded warrants, and accompanying warrants, which closed on March 26, 2026 and generated approximately $30 million in gross proceeds. In March 2026, the company also raised about $19.8 million net through open market sales of nearly 3 million shares under its existing agreement with Jefferies, bringing total outstanding common shares to 22,543,316 and outstanding pre-funded warrants to 4,005,556.
Following these equity financings, Karyopharm expects its existing liquidity, together with cash flow from net product revenue and license and other revenue, to fund its current operating plans into late in the third quarter of 2026, signaling a bolstered near-term cash runway. The transactions underscore the company’s continued reliance on capital markets and strategic investors to support its operations and may reduce immediate financing pressure for stakeholders while modestly diluting existing shareholders.
The most recent analyst rating on (KPTI) stock is a Sell with a $5.00 price target. To see the full list of analyst forecasts on Karyopharm Therapeutics stock, see the KPTI Stock Forecast page.
Spark’s Take on KPTI Stock
According to Spark, TipRanks’ AI Analyst, KPTI is a Neutral.
The score is held down primarily by weak financial performance (persistent losses, cash burn, and negative equity). Technicals also show a clear downtrend. Offsetting factors are a catalyst-heavy clinical timeline plus recent financing/credit amendments that extend runway, but guidance and events still point to meaningful liquidity and execution risk.
To see Spark’s full report on KPTI stock, click here.
More about Karyopharm Therapeutics
Karyopharm Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies, with its operations funded through a combination of equity financing, product revenue, and license and other revenue streams. The company manages its capital structure through private placements and at-the-market offerings to support its operating plans and development programs.
Average Trading Volume: 978,657
Technical Sentiment Signal: Strong Sell
Current Market Cap: $102.2M
For a thorough assessment of KPTI stock, go to TipRanks’ Stock Analysis page.